Insights Into Hodgkin Lymphoma (HL)

Perspectives of community physicians from across the US on the management Hodgkin lymphoma (HL) with regard to clinical and nonclinical factors impacting treatment selection

California – February 18, 2023

Faculty Chair

Joseph Tuscano, MD

UC Davis Health, Sacramento, CA, USA

Northeast – February 25, 2023

Faculty Chair

Joanna Rhodes, MD

Northwell Health, New York, NY, USA

Mid-Atlantic – February 25, 2023

Faculty Chair

Barbara Pro, MD

MD Anderson Cancer Center, Houston, TX, USA

Midwest – March 11, 2023

Faculty Chair

Joanna Rhodes, MD

Northwell Health, New York, NY, USA

Southeast – March 11, 2023

Faculty Chair

TBC

TBC

Northwest – March 18, 2023

Faculty Chair

Krish Patel, MD

Center for Blood Disorders and Stem Cell Transplantation, Seattle, WA, USA

Central – March 18, 2023

Faculty Chair

Radhakrishnan Ramchandren, MD

The University of Tennessee, Knoxville, TN, USA

Southwest – March 25, 2023

Faculty Chair

Jeffrey Schriber, MD, FRCP

Cancer Treatment Centers of America Phoenix, AZ, USA

More Information

  • Sacramento, CA
  • California

More Information

  • Philadelphia, PA
  • Connecticut, Delaware, District of Columbia, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont

More Information

  • Philadelphia, PA
  • Mid-Atlantic Region

More Information

  • Columbus, OH
  • Illinois, Iowa, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio

More Information

  • Atlanta, GA
  • Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia

More Information

  • Seattle, WA
  • Northern California, Oregon, Washington, Idaho, Montana, Wyoming

More Information

  • Nashville, TN
  • Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana

More Information

  • Las Vegas, NV
  • Southern California, Nevada, Utah, Arizona, New Mexico, Colorado

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • Assess advisors’ current management of cHL
  • Gain insights into advisors’ perceptions of available therapies and understanding of data
  • Understand impact of pathways and other nonclinical factors that may affect treatment selection

GEOGRAPHIC REPRESENTATION AND CONTENT DEVELOPMENT

  • Data collection was accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprised 10–15 medical oncologists

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.